BTIG reiterates Buy rating on CareDx stock, sees comeback in 2026

BTIG reiterated its Buy rating for CareDx (CDNA) with a $22 price target, projecting a 'comeback year' in 2026 driven by operational changes and positive sentiment regarding an upcoming Local Coverage Determination (LCD) decision. This outlook comes despite the company's Q2 2025 revenue miss and ongoing Medicare reimbursement concerns, which led to a price target adjustment from $26. The firm notes CareDx's current valuation at ~1.5x its 2026 revenue estimate, significantly below historical peer multiples, indicating potential upside amidst persistent challenges like reimbursement difficulties and patent litigation.

Analysis

CareDx (CDNA) presents a high-risk, high-reward profile, characterized by significant long-term potential juxtaposed with considerable near-term headwinds. Analyst firm BTIG maintains a bullish long-term outlook, reiterating a Buy rating and projecting a "comeback year" in 2026, driven by internal operational and commercial changes. This optimism is partly based on company management's positive sentiment regarding an upcoming final Local Coverage Determination (LCD) decision. The core of the bull thesis rests on a valuation argument: CDNA currently trades at approximately 1.5 times BTIG's 2026 revenue estimate, a steep discount to historical peer multiples of 3x-7x. However, this potential is clouded by immediate challenges. The company's most recent Q2 2025 earnings report was mixed, beating EPS expectations with $0.10 against an anticipated loss, but missing on revenue by 4.33% ($86.7 million reported vs. $90.62 million expected). Furthermore, BTIG lowered its price target to $22.00 from $26.00 specifically due to concerns over Medicare reimbursement proposals, a risk echoed by William Blair's initiation of coverage with a Market Perform rating, citing reimbursement difficulties and patent litigation as key hurdles.

Key Decisions for Investors

• Investors with a higher risk tolerance and a long-term horizon could consider the stock, as the current valuation at 1.5x 2026 estimated revenue presents a significant potential upside if the company's turnaround materializes.
• The primary catalyst to monitor is the final Local Coverage Determination (LCD) decision, anticipated by mid-2026, which represents a critical binary event that could either substantially de-risk the stock or invalidate the current bull thesis.
• Given the recent revenue miss, ongoing reimbursement pressures, and active patent litigation, investors should anticipate continued share price volatility and scrutinize upcoming quarterly reports for evidence that operational changes are successfully improving top-line performance.
• The conflicting analyst ratings warrant a cautious approach; any investment should be sized to reflect the significant event risk associated with future regulatory decisions and ongoing litigation.